SCHEMBL13802490

SCHEMBL13802490

CN(C)C(=O)c1ccc([N+](=O)[O-])cc1NCc1cc(Cl)cc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
SERPINE1 P05121 1/20 0.47
RAB9A P51151 2/20 0.46
MAPT P10636 9/20 0.46
KMT2A Q03164 8/20 0.46
MEN1 O00255 7/20 0.46
GAA P10253 3/20 0.46
ACLY P53396 1/20 0.46
CRHBP P24387 3/20 0.45
CRHR2 Q13324 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HTT P42858 1/20 0.45
MITF O75030 1/20 0.45
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13802443 0.78 MAPT (0.74) SERPINE1RAB9AMAPTKMT2AMEN1
SCHEMBL13802486 0.78 MAPT (0.56) RAB9AMAPTKMT2AMEN1GAA
SCHEMBL13802458 0.74 MAPT (0.48) L3MBTL1RAB9AMAPTKMT2AMEN1
SCHEMBL13802482 0.74 MAPT (0.52) L3MBTL1RAB9AMAPTKMT2AMEN1
SCHEMBL3190849 0.74 L3MBTL1 (0.65) L3MBTL1RAB9AMAPTKMT2AMEN1
SCHEMBL28960367 0.74 L3MBTL1 (0.57) L3MBTL1RAB9AMAPTKMT2AMEN1
SCHEMBL5396641 0.71 L3MBTL1 (0.69) L3MBTL1MAPTKMT2AMEN1GAA
SCHEMBL9178137 0.71 L3MBTL1 (0.53) L3MBTL1RAB9AMAPTKMT2AMEN1
SCHEMBL27711268 0.70 MAPT (0.65) L3MBTL1SERPINE1RAB9AMAPTKMT2A
SCHEMBL2569392 0.70 L3MBTL1 (0.67) L3MBTL1MAPTKMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 L3MBTL1 4682/4885SERPINE1 1045/4885RAB9A 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.